Dengue Vaccine Recommendations

Below are summaries of recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP). For the full text of the recommendations, see Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.

Dengue vaccine is recommended for adolescents who are:

9–16 years old
Live in areas where dengue occurs frequently or continuously including:
- American Samoa
- Puerto Rico
- U.S. Virgin Islands
- Federated States of Micronesia
- Republic of Marshall Islands
- Republic of Palau
Have laboratory-confirmed evidence of previous dengue infection including:
- Positive dengue RT-PCR test result, or
- Positive dengue NS1 antigen test result, or
- Positive results on a pre-vaccination screening dengue virus IgG testing process meeting specific performance standards
- For more information, see Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue Vaccine.

Contraindications and Precautions

Do not administer dengue vaccines to

A person who lacks laboratory evidence of previous dengue infection
A person who has ever had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of this vaccine
A person who has a severe allergy to any vaccine component (see the Dengvaxia package insert)
A person with severe immunodeficiency or immunosuppression due to underlying disease or therapy, including persons with symptomatic HIV infection or CD4+ T-lymphocyte count of <200/mm³.
A person who lacks laboratory evidence of a previous dengue infection

Healthcare providers should weigh the risks of vaccination against the risk for dengue for the following populations: